An interventional study of Moderate-intensity statin monotherapy and Ezetimibe or ezetimibe-statin combination therapy in Dyslipidemia Associated With Type II Diabetes Mellitus, sponsored by Sin Gon Kim. Recruiting at 2 sites in South Korea. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Sin Gon Kim · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies in Dyslipidemias with a site in Korea, Republic of — 30 open to participants now, 39 under way, 5 of them phase 3. Dyslipidemias · Korea, Republic of.
Among the 155 studies in Dyslipidemias with a site in Korea, Republic of, this one is the 7th largest by planned enrollment of the 124 interventional ones that give a count, is one of 8 that started in 2026, is one of 13 with no phase, reaches primary completion later than 36 of the 38 other live ones, and was the 143rd registered.
1,251 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.
Browse Dyslipidemias studies →30 of the 155 studies in Dyslipidemias with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Korea United Pharm. Inc. · Sites in Korea, Republic of
Ages 19–54 · Healthy volunteers
Yonsei University · Sites in Korea, Republic of
Ages 19–85
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 18–100
Korea United Pharm. Inc. · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
Ahn-Gook Pharmaceuticals Co.,Ltd · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,186 is above the median of 100 across 988 interventional studies indexed under Dyslipidemias.
Median enrollment 80 across the 124 interventional studies, 5,000 across the 31 observational. Of the 99 that completed or were terminated, 3 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 155 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Sin Gon Kim as lead sponsor.
Sin Gon Kim has 1 study filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
6 of the studies in Dyslipidemias with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07523971JW PharmaceuticalEfficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study | 2026-12 |
| NCT05365425Seoul National University Bundang HospitalCholine Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia | 2026-12-31 |
| NCT05365438Seoul National University Bundang HospitalAtmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia | 2026-12-31 |
| NCT06293417Korea University Anam HospitalTo Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM | 2027-02-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 155 studies in Dyslipidemias with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Statins are the cornerstone of cardiovascular disease (CVD) prevention through the lowering of low-density lipoprotein cholesterol (LDL-C). While the benefits of intensive LDL-C lowering are well-established for secondary prevention, evidence remains insufficient for primary prevention in the elderly-specifically for individuals aged 70 years or older with type 2 diabetes who have no prior history of atherosclerotic cardiovascular events.
Current guidelines generally recommend moderate-intensity statins for this population based on extrapolated data. However, there is a significant evidence gap regarding whether these older adults, who have not yet experienced a cardiovascular event, derive the same risk-benefit ratio from pharmacological intervention as younger or secondary prevention groups. Furthermore, while ezetimibe (alone or in combination) is an effective alternative for patients with established disease, its efficacy as a primary prevention strategy in older diabetic patients has not been rigorously confirmed through randomized controlled trials (RCTs).
Therefore, this study specifically focuses on the primary prevention setting, aiming to determine whether individualized LDL-C target-based therapy is non-inferior to standard moderate-intensity statin therapy in preventing first-time cardiovascular events among older patients with type 2 diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Statin monotherapy with approved medications.
Drug: Moderate-intensity statin monotherapy
The investigator will establish individualized LDL-C targets (\<55 mg/dL or \<70 mg/dL or \<100 mg/dL) by considering each patient's cardiovascular risk, life expectancy, risk of adverse drug reactions, comorbidities, and personal preferences. The decision-making process will be shared with the patient to ensure that individual needs are addressed.
Drug: Ezetimibe or ezetimibe-statin combination therapy
Atorvastatin 10 mg, 20 mg, or 40 mg, or rosuvastatin 5 mg, 10 mg, or 20 mg will be administered for up to 3 years. If the LDL-C is ≥100 mg/dL, the investigator may adjust the statin intensity based on the patient's health status.
Treatment will consist of non-pharmacological interventions or marketed medications, including low-dose statins (atorvastatin 5 mg or 10 mg, rosuvastatin 2.5 mg or 5 mg) in combination with ezetimibe 10 mg, or fixed-dose combinations (rosuvamibe 10/2.5 mg, atorvabmibe 10/5 mg, or Rosuzet 10/2.5 mg), for up to 3 years. If the pre-specified LDL-C target is not achieved or drug intolerance occurs, adjustments in dosage or medication will be made.
Time from the date of randomization to the first occurrence of a major adverse cardiovascular event (MACE)
Major adverse cardiovascular event (MACE) includes death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, hospitalization due to heart failure, coronary revascularization, or all-cause death.
Time frame: 0, 3, 12, 24, 36 months
Time from the date of randomization to the first hospitalization due to the following events or to the first occurrence of such events, whichever occurs earlier : (1) ischemic heart disease, (2) cerebrovascular disease, (3) heart failure, (4) peripheral
Time frame: 0, 3, 12, 24, 36 months
Time from the date of randomization to the first occurrence of all-cause hospitalization or all-cause death, whichever occurs first
Time frame: 0, 3, 12, 24, 36 months
Serum lipid levels from baseline at each assessment time point
Time frame: 0, 3, 12, 24, 36 months
Serum lipid changes from baseline at each assessment time point
Time frame: 0, 3, 12, 24, 36 months
Patterns of study drug use
Time frame: From baseline up to 36 months
Incidence rates and characteristics of adverse events, adverse drug reactions, and serious adverse events
Time frame: From baseline up to 36 months
Incidence rates and characteristics of adverse events of special interest (AESI)
Adverse events of special interest (AESI): (1) Elevation of aminotransferase levels, (2) Rhabdomyolysis/myopathy, (3) Gastrointestinal problems
Time frame: From baseline up to 36 months
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2029, 45 months after the start.
Of 194 non-industry interventional studies with no phase under Dyslipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 42. This study's planned 45 months is above that.
Counting every sponsor, half of 205 studies reached it within 16 months; a quarter within 8 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.